Please login to the form below

Not currently logged in
Email:
Password:

Ferring appoints executive VP and chief medical officer

Professor Klaus Dugi joins the pharma group from Boehringer Ingelheim

Klaus DugiFerring Pharmaceuticals has appointed professor Klaus Dugi as its executive vice president and chief medical officer; roles that will see him take the helm of its global medical affairs, quality assurance and pharmacovigilance business.

Prior to his new role, Professor Dugi has held various leadership roles at Boehringer Ingelheim, including vice president, global affairs, chief medical officer, and most recently managing director UK and Ireland.

Michel Pettigrew, president of the executive board and chief operating officer, Ferring Pharmaceuticals, said: “Making the industry more patient-centric has always been a top priory for Professor Dugi, and this is perfectly aligned with our company philosophy and commitment so solving unmet patient needs, particularly in the area of reproductive and maternal health.”

Additionally, Professor Dugi will also be a member of the Swiss group’s medical board, effective immediately.

12th October 2017

From: Sales

Share

Tags

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Market Access Transformation

Founded in 201, Market Access Transformation (MAT) specializes in developing agile technology platforms that enable the healthcare community to exchange...

Latest intelligence

Webinar:
Securing a future for telehealth with immersive market research insights...
Accelerating patient recruitment in clinical trials with the Clinical Enrolment Managers (CEMs)
How Innovative Trials' global Clinical Enrolment Managers (CEMs) give clinical trial sites the local touch...
Six ways to improve diversity in clinical trials
Diversity is becoming increasingly important as a focus of clinical trials. This whitepaper gives six approaches that could be implemented to help make diversity a bigger focus on your clinical...